Skip to main content
Article thumbnail
Location of Repository

From bench to bedside: current and future applications of molecular profiling in renal cell carcinoma

By Androu Arsanious, Georg A Bjarnason and George M Yousef


Among the adult population, renal cell carcinoma (RCC) constitutes the most prevalent form of kidney neoplasm. Unfortunately, RCC is relatively asymptomatic and there are no tumor markers available for diagnostic, prognostic or predictive purposes. Molecular profiling, the global analysis of gene and protein expression profiles, is an emerging promising tool for new biomarker identification in RCC. In this review, we summarize the existing knowledge on RCC regarding clinical presentation, treatment options, and tumor marker status. We present a general overview of the more commonly used approaches for molecular profiling at the genomic, transcriptomic and proteomic levels. We also highlight the emerging role of molecular profiling as not only revolutionizing the process of new tumor marker discovery, but also for providing a better understanding of the pathogenesis of RCC that will pave the way towards new targeted therapy discovery. Furthermore, we discuss the spectrum of clinical applications of molecular profiling in RCC in the current literature. Finally, we highlight some of the potential challenging that faces the era of molecular profiling and its transition into clinical practice, and provide an insight about the future perspectives of molecular profiling in RCC

Topics: Review
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (1997). A: Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised
  2. (2005). Belldegrun AS: Postoperative surveillance protocol for patients with localized and locally advanced renal cell carcinoma based on a validated prognostic nomogram and risk group stratification system.
  3. (2001). Belldegrun AS: Validation of the ucla integrated staging system for patients with renal cell carcinoma.
  4. (2001). et al.: Improved prognostication of renal cell carcinoma using an integrated staging system.
  5. (2003). et al.: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer.
  6. (2007). et al.: Sorafenib in advanced clear-cell renal-cell carcinoma.
  7. (2005). FJ: Renal-cell carcinoma.
  8. (2005). Independent validation of the 2002 American Joint Committee on cancer primary tumor classification for renal cell carcinoma using a large, single institution cohort.
  9. (1999). Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet
  10. (1996). Nanus DM: Renal-cell carcinoma.
  11. (2005). Prognostic factors and survival after pulmonary resection of metastatic renal cell carcinoma. Eur Urol
  12. (1999). Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.
  13. (2005). Randomized phase III trial of high-dose interleukin2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.
  14. (2007). Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
  15. (1999). Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.
  16. (2007). The follow-up management of non-metastatic renal cell carcinoma: definition of a surveillance protocol.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.